Pfizer Stock News

Maybe. But neither is likely to knock Dupixent off its perch.

Public Health ''Experts'' Have A New COVID Boogeyman Called "Stealth" Omicron Deaths involving patients infected with COVID have risen in the US recently, even as case numbers have continued to decline. But what''s even more concerning is that a growing percentage of overall deaths are being attributed to ''breakthrough'' infections involving vaxxed & booster patients ). It''s just the latest example of how narratives pushed by the government change as they are confronted with contradictory evidence (this time, it''s the notion that the vaccinated would escape death, something we now know to be untrue). Despite this, it seems like people across the US and around the world are growing more bold as the longing t o return to "normal" intensifies. In northern Europe, Denmark and the Netherlands are abandoning COVID restrictions even as the outbreak has persisted. At the same time, scientists around the world have found something new with which to prime the public for Booster No. 4 (now that both Pfizer and Moderna have started human trials for their omicron-focused jabs): A new sub-variant called "stealth omicron", also known as BA.2.

Photo by Matt Koffel on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. For Quipt Home Medical (NASDAQ: QIPT ), a specializer in ventilator equipment and aids, the COVID-19 pandemic presented a significant chance to bring additional value to society. With a critical shortage of ventilators and hospitals experiencing a surge of patients , the company reports that its home ventilation and oxygen therapy solutions provided many with an outlet for essential health products and services. In tandem with pharmaceutical companies such as Pfizer Inc. (NYSE: PFE ) and hospital providers like Community Health Systems Inc. (NYSE: CYH ), companies like Quipt round out the home-based side of medical devices and care. With the Full story available on Benzinga.com

Bank of America Global Research released their stock ratings and price targets for 15 biopharmaceutical companies as part of their recent report titled 4Q21 Biopharma Preview - What We Think Will Matter. Of these 15, BofA cited Pfizer and BioMarin as being positioned particularly strongly as earnings season starts to kick off.

Regulator heavily critical of aides to Ursula von der Leyen in relation to Covid vaccine messages An investigation by an EU watchdog into text messages sent by European commission president Ursula von der Leyen to Pfizers chief executive has found the European Commission guilty of maladministration. Von der Leyens aides are heavily criticised in the ruling from Emily OReilly, the European ombudsman, for their handling of requests for publication of the messages sent during negotiations over vaccine purchases. Continue reading

COVID-19 Can Be Stopped Without Massive Vaccination: Dr. Peter McCullough Authored by Harry Lee and Steve Lance via The Epoch Times (emphasis ours), COVID-19 can be stopped without massive vaccination, renowned cardiologist and epidemiologist Dr. Peter McCullough told NTDs Capitol Report program during the Defeat the Mandates march in Washington D.C., on Jan. 23. According to McCullough, early treatment and natural immunity are safe and effective against COVID-19, but federal health agencies have ignored these in a push for vaccines, the broad use of which is not needed. The government has certainly been in an oblivion in terms of early treatment, he said. Thousands of people turned out to march in protest against COVID-19 vaccine mandatesone of the largest U.S. events against the mandates since the start of the pandemic. Our CDC, FDA, and NIH have had no effective messaging on early treatment, even the emergency use authorized monoclonal antibodies, which are safe and effective, McCullough said. And even on the new Merck and Pfizer drugs, which theyre basically absent in terms of the media, despite being recently distributed across the United States. Early effective treatment of any disease can help avert progression to more serious illness, with an additional benefit of reducing the burden on health care systems, and in a seperate interview, McCullough claimed that 95% of the COVID deaths could have been prevented by early treatment

Melbourne-based content creator Tee Jay, who runs the Instagram and TikTok account wippa_snippa, shared the unusual dilemma with her audience on Sunday.

FDA Asks Court To Delay First 55K Batch Of COVID Docs; Pfizer Moves To Join Case Authored by attorney Aaron Siri via Injecting Freedom (emphasis ours), As explained in prior posts , in a lawsuit seeking all of the documents the FDA relied upon to license Pfizers COVID-19 vaccine, a federal judge shot down the FDAs requested rate of 500 pages per month and instead ordered the FDA to produce at the rate of 55,000 pages per month starting on March 1. Since the government has trillions of dollars of our money, it is putting it to good use by fighting to assure that the public has the least amount of transparency possible. To that end, it has now asked the Court to make the public wait until May for it to start producing 55,000 pages per month and, even then, claims it may not be able to meet this rate. The FDAs excuse? As explained in the brief opposing the FDAs request, the FDAs defense effectively amounts to claiming that the 11 document reviewers it has already assigned and the 17 additional reviewers being onboarded are only capable of reading at the speed of preschoolers.

PALM BEACH, Fla. , Jan. 27, 2022 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - According to International Agency for Research on Cancer (IARC) published by the World Health Organization (WHO) in 2018, breast cancer ranks as the fifth leading cause of deaths in women; accounting for 627,000 deaths every year. Moreover, as per estimates of the American Cancer Society, in U.S., 266,120 new cases were expected to be diagnosed in women by 2018. Furthermore, aging is considered as one of the greatest risk factors. According to Cancer Treatment Centers of America, women above 60 years of age are more likely to be diagnosed and only about 10% to 15% of cases occur in women younger than 45 years of age. High prevalence of the disease coupled with patent expiry are some of the major factors influencing investment in research and development of new products. The R&D spending from companies like Johnson & Johnson Services, Inc.; Merck & Co., Inc.; Celgene Corporation; Pfizer, Inc.; GlaxoSmithKline plc; Sanofi; and AbbVie, Inc. has increased exponentially.

Moderna Inc (NASDAQ: MRNA ) has started a mid-stage study, testing a booster dose of its COVID-19 vaccine specifically designed to target the omicron coronavirus variant . Additionally, Moderna announced the publication of neutralizing antibody data against the Omicron variant six months following a booster dose in The New England Journal of Medicine. The Company said that while the third shot of its original coronavirus vaccine increased neutralizing … Full story available on Benzinga.com

British PM braces for partygate report as England scraps indoor mask requirements and vaccine passports; Moderna follows Pfizer in launching trial to target Omicron Tory MPs to send letters of no confidence in PM after partygate report Netherlands lifts toughest curbs, with France and Denmark to follow Coronavirus vaccines may reduce long Covid risks, study finds US donated 400m Covid vaccine doses to 112 countries, says White House Germany to crack down on Covid protesters in yellow star badges New Zealand braces for shift from Covid zero to Covid acceptance Hello and thanks for joining us for all the latest Covid developments this Thursday. Im Samantha Lock and Ill be here for the next hour or so before my colleague Martin Belam takes the reins from London. Continue reading

Doctor''s Organization Has Treated Over 150,000 COVID-19 Patients With 99.99% Survival Authored by Meiling Lee via The Epoch Times (emphasis ours), A doctor who has been offering free telehealth services to COVID-19 patients during the pandemic says that early treatment for COVID-19 works, claiming that he has a 99.99 percent survival rate. “We have a team of volunteer free doctors that donate their time to help treat these patients that come to us,” Dr. Ben Marble, the founder of myfreedoctor.com, an online medical consultation service, said at a roundtable discussion hosted by Sen. Ron Johnson (R-Wis.) on Jan. 24. He added, “ We deliver the early treatment protocols to them as early as we can, and we have a 99.99 percent survival rate. So, I believe myfreedoctor.com, the free volunteered doctors have settled the science on this—early treatment works, period!” A paramedic prepares an ambulance at Hudson Regional Hospital in Secaucus, N.J., on Dec. 11, 2020. (Kena Betancur/AFP via Getty Images) Marble was answering Johnson’s question about what people can do if they or their loved ones have COVID-19.

The coronavirus variant has quickly become dominant in many parts of the world, driving up infections and straining healthcare systems.

Pfizer Begins Human Trials For New Omicron Vaccine As US Cases Tumble Pfizer and its partner BioNTech just launched the first human trials of their revised COVID vaccine which has been adapted to try and provide better protection against the omicron variant. Shortly after the emergence of omicron in late November, Pfizer and its rivals all promised to produce another generation of vaccines, claiming they could have them ready within three months. So far at least, that timeline appears mostly on track. However, an even more important question for Pfizer might be this: who will even need these jabs when they''re ready, since it looks like the omicron wave numbers will have finally tapered off by the time the trials are completed. At any rate, the two firms said Tuesday they had begun enrolling adults ages 18 to 55 for trials taking place in the US and South Africa. The trials will seek to examine the safety, tolerability and, most importantly, the immune response generated by the new vaccines, per WSJ.

Stocks Analysis by Zacks Investment Research covering: Citigroup Inc, Mastercard Inc, CSX Corporation, Exelon Corporation. Read Zacks Investment Research''s latest article on Investing.com